IMMUTEP LIMITED - AMER

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

28 أبريل 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

30 مارس 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

24 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022

18 مارس 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

18 مارس 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

10 مارس 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

24 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

18 فبراير 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

11 فبراير 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep to Present at February Investor Conferences

31 يناير 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

25 يناير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep Advances IMP761 Manufacturing

16 ديسمبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

02 ديسمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

19 نوفمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

15 نوفمبر 2021 08:00:03 بحسب Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

15 نوفمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

09 نوفمبر 2021 08:05:00 بحسب Nasdaq GlobeNewswire

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

09 نوفمبر 2021 08:00:04 بحسب Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

02 نوفمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 أكتوبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire